Recent Advances in the Development of Anti-allergic Drugs  by Nagai, Hiroichi et al.
Recent Advances in the Development
of Anti-allergic Drugs
Hiroichi Nagai1, Hitomi Teramachi1 and Teruo Tuchiya1
ABSTRACT
Research over the past decade has provided information concerning the onset and treatment of allergic dis-
eases, including bronchial asthma, allergic rhinitis and atopic dermatitis. Recent studies also indicated that al-
lergic inflammation is the basic pathophysiology of allergic diseases and is closely associated with their pro-
gression and exacerbation. Our understanding of the mechanism of allergic inflammation with regard to thera-
peutic agents has improved as a result of immunological and molecular biological studies. While much effort
has been paid to developing a new anti-allergic drug, allergic disease has yet to be completely conquered.
More extensive research will allow the development of new therapeutics to combat allergic diseases. This arti-
cle provides an overview of recent advances in the development of anti-allergic drugs．
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INTRODUCTION
The increasing incidence in allergic diseases, includ-
ing allergic bronchial asthma, allergic rhinoconjunc-
tivitis and atopic dermatitis , is as yet unexplained .
Pathomechanistic studies have indicated that allergic
inflammation contributes to onset of acute andor
chronic symptoms of allergic diseases. Despite our
understanding of the underlying mechanism, there
are some therapeutic problems because the preva-
lence of allergic diseases has increased dramatically
in recent decades . 1-5 A significant amount of re-
search is currently focused on explaining this rise in
the number of cases of allergic diseases.6-15
Bronchial asthma , a typical allergic disease , is
thought to be caused by subchronic eosinophilic epi-
thelial desquamative inflammation of the airway .
Other allergic diseases such as allergic rhinitis and
atopic dermatitis are also inflammatory diseases, as
indicated by the names. Thus, allergic inflammation
is the basic pathophysiology of allergic diseases and
is closely associated with progress and exacerbation
of the diseases.
Based on the information described above, a suit-
able target for the therapeutic treatment of allergic
diseases might be the suppression of allergic inflam-
mation. As shown in Figure 1, allergic inflammation
is initiated by the activation of adoptive immune re-
sponse. This immune system results from allergen
impact on the mucosal surface . Whole allergen is
taken up by antigen-presenting cells and peptides are
presented to T cells, resulting in T cell activation and
elaboration of cytokines. This is the onset of immune
response to produce immunoglobulin. In a Type I al-
lergic reaction, immunoglobulin E (IgE) is produced,
which is fixed to the mast cell through Fcε receptor.
Cross-linking of allergen-specific IgE leads to the re-
lease of histamine , leukotrienes ( LTs ) and
prostaglandin D2 from mast cells . These chemical
mediators introduce immediate phase reactions such
as bronchospasm, sneezing and itching in the tissues.
Interleukin-4 (IL-4), IL-13 and other mediators includ-
ing chemokines are generated and released almost 3
to 12 hours after the antigen-antibody combination.
Chemokines attract the eosinophils to the allergic le-
sion. Eosinophil recruitment leads to the release of
toxic proteins and mediators, such as protease and
LTs, causing edema and epithelial cell damage. Then,
tissue remodeling, the repair of injured tissue , oc-
curs. From these basic concepts, current therapeutic
approaches have focused either on the treatment of
allergic inflammation or the rapid relief of severe
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Immediate phase reaction (after few minutes)
Last phase reaction (after several hours)
Fcε receptor
Table 1 The classification of anti-alergic drugs (anti-asthma drug)
DrugsMedicationClassification
1. Inhaled glucocorticoids1. Taken daily on a long-term basisControlers
2. Anti-alergic agents2. Prophylactic and preventive medication
Anti-histamine, Leukotriene inhibitor, 
Thromboxane A2 inhibitor, Th2 cytokine
inhibitor, Mast cel stabilizer, etc.
1. Rapid-acting inhaled β2-agonists1. Taken on demandRelievers









Table 2 Histamine receptor
AntagonistAgonistExpressionReceptors
Ethanolamine2-methyl histamineNerve cels, airway and vascular smooth mus-
cles, neutrophils, eosinophils, monocytes, DC, 




4-methyl histamineNerve cels, airway and vascular amooth mus-
cles. Neutrophils, eosinophils, monocytes, DC, 




α-methyl histamineHistaminergic neurons, eosinophils, DC, mono-
cytes
Low expression in peripheral tissues
H3
――Eosinophils, neutrophils, DC, T cels, B aso-
phils, mast cels
Low expression in nerve cels, hepatocytes, pe-
ripheral tissues
H4
symptoms.16-20 The former kind of therapeutics are
called “controller” and the later type are called “re-
liever.” The typical controller is topical glucocorticoid
and the reliever is a bronchodilator and anti-
histamine. The classification and typical characters of
both kinds of drug are outlined in Table 1.
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Fig. 2 The 5-lipoxygenase (5-LO) pathway of arachidonic acid (AA) and inhibitors. FLAP: 5-















Pharmacoligical action in allergy
Broncho spasm, Plasma exceration
Vascular effects, Mucus secretion
Eosinophil recruitment, Muscle proliferation
DC migration, Participation of IL-13 action
Table 3 Summary of present status and recommenda-
tions for third generation antihistamines by CONGA
1) The anti-inflammatory or anti-alergic properties should 
be demonstrable in vivo in humans, at therapeutic 
doses and under natural exposure to the ofending aler-
gens
2) The therapeutic index of an antihistamine, defined as its 
benefit-risk ratio, is a more important concept than ei-
ther potency (preclinical studies) or eficacy (clinical tri-
als)
3) The lack of cardiac toxicity must be retained in the devel-
opment of novel congeners that enter the market in the 
future
4) The drug should not afect any CYP isozyme function, 
should not displace  protein bound medications and 
should not afect active transport mechanism (i.e. P-gly-
coprotein)
5) Non-sedative properties should be defined by measur-
ing a) incidence of subjective sleepiness  b) objective 
cognitive and psychomotor function  c) positron em-
mision tomography (PET) measurement of H1 receptor 
occupancy
6) A new antihistamines based on the theoretical proper-
ties should however, be proven to have distinct clinical 
advantage over existing drugs
There are numerous discussions concerning a suit-
able nomenclature of anti-allergic drugs. The nomen-
clature can reflect the target cells and molecules
which participate at the onset and development of al-
lergic diseases. Therefore, in this manuscript, anti-
allergic drugs involve antihistamines, leukotriene in-
hibitors , thromboxane inhibitors , Th2 cytokine in-
hibitors, mast cell stabilizers and agents for new tar-
get cells or molecules. The recent advances of thera-
peutic agents for allergic diseases will be described in
this manuscript．
ANTI-HISTAMINES
During the past decade, there have been major ad-
vances in our understanding of histamine, histamine
receptors and histamine H1 antagonists. Histamine
has played a central role in our understanding of al-
lergic reaction. It was the first mediator to be associ-
ated with allergic reaction and was the first whose in-
hibition proved useful in the management of dis-
eases . For many years , histamine receptors have
been characterized using a pharmacological ap-
proach. Recently, a cDNA clone encoding the H1 re-
ceptor has been cloned in human leukocytes and the
structure of the H1 receptor protein has been de-
duced along with several other histamine receptors
(Table 2). These findings improved the development
of new antihistamines, especially H1 receptor antago-
nists．
The first-generation antihistamines were defined
by their H1 receptor blocking activity , and despite
pronounced unwanted side-effects they are still
widely used.21-25 The problems with systemic side-
effects, especially sedation and dry mouth, stimulated
the pharmacological research to develop a second
generation of drugs that were ostensibly free of these
properties and more efficacious．
The second-generation antihistamines are called
non-sedating H1 antagonists because of their low
penetration through the blood-brain barrier . Com-
pared with the first generation agents , they are
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Table 4 The inhibitors of leukotrienes
Cys LT1 antagonist5-LO inhibitor
PranlukastMonterukastZafielkastZeileuton
4501040600Oral Dosage (mg/day)
 2 1 2  4Administration (times/day)







5-LO: 5-lipoxygenase　Cys LT1: cystenyl leukotriene 1 receptor　ND: Not done
Table 5 The role of thromboxane A2 in alergic condition 
in human and experimental animals
1. Alergic bronchial asthma―late asthmatic response
2. Alergic rhinitis―sneezing, rhinorhea, rhinostenosis
3. Atopic dermatitis―the relationship between TP polymor-
phism and IgE production
4. Alergic conjunctivitis
Table 6 Clinical and basic pharmacological profile of Sup-
latast
1. Decrease in the number of eosinophils in sputam of asth-
matic patients and in blood of atopic dermatitis patients
2. Decrease in serum IgE level in alergic asthma, alergic 
rhinitis and atopic dermatitis patients
3. Decrease in the production of Th2 cytokines by T cels 
from alergic patients
4. Inhibition of IgE production in mice and rats
5. Inhibition of the production of Th2 cytokines by murine 
splenocytes
6. Inhibition of the onset and development of experimental 
alergic asthma, rhinitis, dermatitis and eosinophilia in mi-
ce, rats and guinea pigs
known for their minimal central nervous system ef-
fect. Many of the second-generation antihistamines
undergo extensive first pass metabolism in the liver
by the cytochrome p450 (CYP) enzymes. Drugs such
as ketoconazole , erythromycin and azithromycin ,
which affect the activity of CYP, can lead to build up
of the parent antihistamine compound, thus increas-
ing the risk of side-effects. It has been demonstrated
that the ingestion of grapefruit juice can inhibit isoen-
zyme CYP3A in the liver. Thus grapefruit juice may
increase the concentration of antihistamines, such as
terfenadine, loratadine and astemizole which are me-
tabolized by CYP3A4．
Additionally, life-threatening adverse cardiac side
effects, QT prolongation and torsades de pointes ven-
tricular tachyarrhythmia have been demonstrated to
be associated with the use of some second-generation
antihistamines. These effects are due to the direct
blockade of a specific class of potassium channels
controlling the repolarization phase of the cardiac ac-
tion potential and are not related to the blockade of
H1 receptor . Thus this cardiotoxicity by second-
generation antihistamines is not a class effect．
As a direct result of these problems , a third-
generation anti-histamines has emerged.26 The term
‘ third-generation’ or ‘multifunctional’ antihistamine
was employed by Hanifin,27 Sabbah,28 Caproni et al.29
and ourselves30 for describing the pharmacological
profiles of ketotifen , terfenadine and cetirizine , re-
spectively. However, clear criteria of what this term
means are still uncertain . In 2003, a Consensus
Group on New Generation Antihistamines (CONGA)
has been set up with the support of the ‘British Soci-
ety for Allergy and Clinical Immunology’ to address
the meaning of the third-generation antihistamines.
An internal expert panel of scientists and clinicians
outside the pharmaceutical industry convened to
form a CONGA and reported in Clin. Exp. Allergy,
2003. 26 An exclusive summary was produced with
recommendations in six areas as indicated in Table 3.
Published information concerning H 1 antihista-
mines suggests that none of them can be classified as
a true third-generation antihistamine. Rationalization
is required to develop a new class of antihistamines．
LEUKOTRIENE INHIBITORS
LTs are derived from membrane constituent arachi-
donic acid and induce many allergic symptoms, in-
cluding airway smooth muscle contraction , hyper-
secretion , eosinophilia and airway wall remodel-
ing.31-35
As shown in Figure 2, recent research revealed the
additional biological activity of LTs in allergic reac-
tion. One explanation is the role of LTs in dendritic
cell (DC) migration36 and another is the participation
of LTs in the pathological action of IL-13.37 Recent
studies by Robbiani et al.36 indicated that LTs play a
role in the antigen-stimulated migration of DC
through the activation of multidrug resistance-
associating protein 1 (MRP 1 ) and chemokine
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Table 7 New celular and molecular targets and concomitant approaches for anti-alergic drug development
ApproachTarget
Epitopes, TCR activation status receptorsAlergen
Tryptase, Elastase, Kimase, MMP inhibitorsProtease
(Th2) GATA-3, FOG-1, CD28, CTLA-4T cel modulator
(Th1) CpG oligodeoxynucleotides, T-bet
(T) Macrocyclic immunosuppressant
TNF antagonist, GM-CSF antagonist, IL-4 antagonist, IL-5 antagonist, IL-13 antagonist, IL-10, IL-12, IL-
18, IFN-γ
Cytokines
Th2 related chemokines receptor antagonist, CCR-3 antagonist, IL-8 receptor antagonistChemokines
VLA-4 antagonist, selectin antagonist, ICAM-1 and VCAM-1 antagonistsAdhesion molecule
Humanized anti-IgE antibodiesIgE antibody
Cys LT1 and LT2 antagonist, 5-LO inhibitor, LTB4 antagonist, H1 receptor antagonists, Kinin receptor 
antagonist, endothelin antagonist, Tachykinin antagonist, Anti-oxydant, P2Y receptor antagonist
Smal molecules
(CCL19). This suggests that LT may play a role in the
acceleration of antigen presentation in acquired im-
munity. In addition, IL-13 induced airway remodeling
in mice through the generation of LTs which is the
main cause of the onset of airway hyperreactivity ,
eosinophilia and MUC5AC production. This suggests
that IL-13 plays an important role in the onset of air-
way hyperreactivity and contributes to the stimula-
tion of LT generation．
Evidence from several sources indicates an addi-
tional role for LTs in allergic diseases. After the iden-
tification of the chemical structures of LTs, extensive
efforts have been made for cloning of the cysteinyl
LT ( cys-LT ) receptors . It is noteworthy that the
launch of LT antagonists preceded the identification
and cloning of cys-LT receptors. On this basis, many
researchers initiated programs to find either inhibi-
tors of LT biosynthesis or selective receptor antago-
nists．
In the 1990s, the LT approach moved from concept
to proof. This was based on the successful develop-
ment and subsequent launch of three LT antagonists
and one 5-lipoxygenase (5-LO) inhibitor listed in Ta-
ble 4. Three receptor antagonists display significant
structured homology and are highly effective against
LTD4. A common feature of clinical trials with these
three antagonists is an improvement in baseline lung
function in asthma patients but not in non-asthma pa-
tients. This result demonstrates that antagonists do
not have a direct relaxing activity of bronchial smooth
muscle . These improvements are generally in the
range of 25― 50% , although the magnitude of the
changes depends on the symptoms which are meas-
ured by the severity of disease. In addition, many
studies have been carried out with combinations of
cys-LT antagonists and inhaled corticosteroid . 38-40
Generally, treatment of LT antagonists resulted in a
lower dose of inhaled corticosteroid, reducing the se-
verity of asthmatic symptoms.
As for 5-LO inhibitors, many compounds have been
developed but only one drug, zileuton has been regis-
tered for treatment of asthma in the USA. From ob-
servations with 5-LO inhibitors, in particular zileuton,
it appears that the anti-asthmatic effects of 5-LO inhi-
bition and selective cysLT1 receptor antagonists in
asthma patients are indistinguishable. The successful
induction of cys-LT1 receptor antagonists and 5-LO
inhibitors for the treatment of bronchial asthma pro-
vided clinical data that confirmed the LT hypothesis
in asthma, which had taken almost 70 years to evolve
since the original discovery of slow reacting sub-
stance of anaphylaxis．
Unfortunately the clinical role of LTs in other aller-
gic diseases, such as allergic rhinitis and dermatitis,
is still uncertain. Our studies employing 5-LO gene
deficient mice41 suggest low participation of LTs in al-
lergic dermatitis and IgE production (unpublished
data).Further studies to investigate the role of LTs in
other allergic diseases, especially nasal obstruction,
could expand the therapeutic utility of LT inhibitors．
THROMBOXANE A2 (TXA2) INHIBITORS
There is some evidence from basic research and clini-
cal reports to indicate that TxA2 is involved in the on-
set and development of allergic diseases as shown in
Table 5.42-45 There are two types of TxA2 inhibitor in
clinical use in Japan, including one TxA2 synthetase
inhibitor (ozagrel) and two TxA2 receptor antago-
nists (ramatroban and seratrodust). All these TxA2
inhibitors are employed for the treatment of bron-
chial asthma. The efficacy of these agents in asthma
treatment is still under discussion, but the effective-
ness of ramatroban in allergic rhinitis is noteworthy.
Because of the strong expression of TxA2 receptor
mRNA in the nasal mucosa of allergic rhinitis patients
and the positive relationship between TxA2 receptor
polymorphism and IgE production,46 the anti-allergic
action of TxA2 receptor antagonist might be antici-
pated. From the extensive basic and clinical investiga-
tions concerning the efficacy of ramatroban in aller-
gic rhinitis, the drug showed a potent therapeutic ac-
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tivity to several nasal symptoms, especially, nasal ob-
struction. Since several investigators including our-
selves, revealed the efficacy and antagonistic action
of ramatroban against CRTH 2, one of the
prostaglandin D2 receptors , interest in the role of
CRTH2 in the onset of nasal obstruction has in-
creased.42,44 However, further studies are necessary
to fully determine the efficacy of these anti-CRTH2
agents．
TH2 CYTOKINE INHIBITOR
There is now good evidence that allergic diseases are
driven by antigen specific Th2 cells. Recent advances
in understanding the immunology of Th2 cells have
opened up the possibility of specific immunomodula-
tion to control allergic diseases. Our laboratory , in
collaboration with a pharmaceutical company, has in-
vestigated suplatast , a Th2 cytokine inhibitor . 47-50
Suplatast initiates the suppression of IgE antibody
production and eosinophilia by interfering with Th2
cytokine production . In addition , suplatast inhibits
the activation of chloride ion channels on eosinophils
resulting in cell death (unpublished data). The clini-
cal and basic pharmacological profile of suplatast is
summarized in Table 6. This is the first trial to apply
the T cell immunomodulator as a remedy for allergic
diseases.
FUTURE DRUGS
Future strategy aimed at down regulation of the aller-
gic response can be classified into many categories as
indicated in Table 7. While there are numerous possi-
ble strategies to develop a new drug, our interest is
focused on the concept of Th2 dependent allergic in-
flammation in the diseases.
With regard to the suppression of Th2 response,
there are some new trials targeting Th1 response
stimulation, cytokine suppression and other regula-
tory molecules. One of the Th1 stimulators is a plas-
mid vector containing genes that encode allergen ,
namely a DNA vaccine.51,52 This vaccine decreases
Th2-mediated responses, enhances Th1 mediated re-
sponses and suppresses allergic responses in animal
models. Other trials have employed a virus-like parti-
cle to induce interferon producing CD8+T cells and
mucosal DNA vaccines to induce tolerance.53 For ex-
ample, the main peanut allergen gene expression vec-
tor when administered orally caused higher fecal IgA
and serum IgG2a and lowered serum IgE titer and re-
sulted in decreased anaphylactic symptoms . 54
Whether this approach is efficacious will be deter-
mined in further studies．
A particular approach for enhancement of Th1 me-
diated response has been the administration of syn-
thetic oligodeoxynucleotides with immuno-
stimulatory sequences. Strong stimulation was driven
by sequences containing methylated CpG motifs that
are more highly expressed in microbial rather than
vertebrate DNA, and so are recognized as foreign by
the Toll-like receptor in innate immunity. These mo-
tifs indicate the function as Th1 promoting adjuvant
capable of switching the usual Th2 response toward
Th1 response.55-57 Preclinical results are promising,
but the outcome of clinical trials for allergic diseases
is pending．
Some experimental results, including those of our
own , indicate the efficacy of interferons or IL-12
against allergic inflammation.58,59 Contrary to basic
research, these cytokines are ineffective for treating
allergic diseases.60,61 These cytokines, along with re-
lated targets, will have to be monitored in near future.
In addition to TH1 related cytokines, Th2 cytokines
including IL-5 are the target molecule for anti-allergic
agents. As for IL-5 suppression, there are many ex-
periments to support the effectiveness of anti-IL-5
monoclonal antibody at inhibiting allergic dis-
eases.62-66 We have demonstrated the efficacy of anti-
IL-5 monoclonal antibody for allergic airway wall re-
modeling, but not for allergic airway hyperreactivity
in experimental animals.66 Our data is confirmed by
some extensive clinical studies . Holgate et al. re-
ported ineffectiveness of IL-5 monoclonal antibody in
airway hyperreactivity but found it to be effective in
the therapy for allergic eosinophilia.67 Moreover, re-
cent studies by Kay et al. 62 indicated the effective-
ness of anti-IL-5 antibody on airway wall remodeling
in asthma patients. These results stimulated a discus-
sion about the role of IL-5 and eosinophils in the de-
velopment of allergic asthma. Long term treatment of
anti-IL-5 will be necessary to establish the role of IL-5
and eosinophils in bronchial asthma. Regarding the
role of eosinophils, our recent studies employing the
inhibitors of eosinophil chemotaxis indicate the effi-
cacy of eosinophil inhibitors for anti-asthmatic treat-
ment (unpublished data)．
As for IL-13 and IL-9, many investigators reported
that these are potent pathological substances for al-
lergic diseases. Therefore, these two cytokines are
target molecules for anti-allergic agents.63-66 In fact,
mice lacking the gene for IL-13 and IL-9 showed low
hyperresponsiveness and airway inflammation , re-
spectively. However, there has been no report about
the efficacy of the inhibitors against these cytokines
in clinical trials．
In the recent past the use of humanized anti-IgE
antibodies has become a new therapeutic strategy for
allergic diseases.68 Treatment with anti-IgE antibod-
ies leads to a decrease in serum IgE and in the num-
ber of high-affinity IgE receptors on mast cells and
basophiles. These decreases lead to a low excitability
of the effector cells reducing the release of inflamma-
tory mediators. Anti-IgE antibody is expected to be a
promising strategy in near feature．
CONCLUSION
Considerable resources have been focused on reduc-
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ing the incidence of allergic response by modifying
existing therapeutics and developing new anti-allergic
drugs. This manuscript reviewed the current state of
play with regard to the development of anti-allergic
drugs. Extensive research on the mechanism of al-
lergy and therapeutics to combat allergic disease will
give us an opportunity to find new strategies for es-
tablishing effective treatments . Continued research
on the molecular mechanism of allergic disease will
inevitably generate new forms of therapy．
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